Vision Statement

To advance the science of neurotherapeutics and to improve and accelerate the development of new treatments.
# Table of Contents

Meeting Room Layout ..........................................................2-3

Program Schedule .................................................................4

Information Exchange and Poster Presentation Reception ........6

Information Tables ...................................................................6

Annual Business Meeting .......................................................11

Meeting Evaluation/How Do I Obtain CME Credits? .............12

Continuing Medical Education Information ...........................13-14

15th Annual Meeting Program Committee ............................15

ASENT Board of Directors .....................................................16

Schedule-At-A-Glance...........................................................Back Cover
American Society for Experimental NeuroTherapeutics

Ballroom Level

General Session Room

15th Annual Meeting
Conference Level
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 8:05 a.m.</td>
<td><strong>Presidential Welcome</strong>&lt;br&gt;Michael Rogawski, MD, PhD,&lt;br&gt;University of California, Davis</td>
</tr>
<tr>
<td>8:05 a.m. – 8:15 a.m.</td>
<td><strong>Introduction to Neurostimulation</strong>&lt;br&gt;Shaun Comfort, MD, Adaptix Clinical Solutions, LLC</td>
</tr>
<tr>
<td>8:15 a.m. – 9:05 a.m.</td>
<td><strong>Basic Mechanisms of Neurostimulation</strong>&lt;br&gt;Cameron McIntyre, PhD, Cleveland Clinic</td>
</tr>
<tr>
<td>9:05 a.m. – 9:30 a.m.</td>
<td><strong>Neurostimulation for the Treatment of Neurological Disease</strong>&lt;br&gt;Jaimie Henderson, MD, Stanford University</td>
</tr>
<tr>
<td>9:30 a.m. – 10:00 a.m.</td>
<td><strong>Intracortical Neural Interfaces for the Restoration of Function</strong>&lt;br&gt;Leigh Hochberg, MD, PhD, Massachusetts General Hospital</td>
</tr>
<tr>
<td>10:00 a.m. – 10:20 a.m.</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>10:20 a.m. – 10:40 a.m.</td>
<td><strong>The Emergence of Therapeutic Neurostimulation</strong>&lt;br&gt;John Reppas, MD, PhD, Neurotechnology Industry Organization</td>
</tr>
<tr>
<td>10:40 a.m. – 11:00 a.m.</td>
<td><strong>Neurostimulation Devices: A Regulatory Perspective</strong>&lt;br&gt;Victor Krauthamer, PhD, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>11:00 a.m. – 12:00 p.m.</td>
<td><strong>Moderated Panel Discussion</strong></td>
</tr>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td><strong>Lunch On Your Own</strong></td>
</tr>
</tbody>
</table>
### Program Schedule (Continued)

**THURSDAY, FEBRUARY 28, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m. – 4:30 p.m.</td>
<td>Brave New World: Use of the Internet and Social Media to Conduct Clinical Trials</td>
<td>Crystal Ballroom – Haverford Suite</td>
</tr>
</tbody>
</table>

**Program**

Chair: Nancy Santilli, BSN, MSN, Endo Pharmaceuticals, Inc.

1:30 p.m. – 1:40 p.m.  **Introduction to the Session and the Power of Social Media**
Nancy Santilli, BSN, MSN, Endo Pharmaceuticals, Inc.

1:40 a.m. – 2:00 p.m.  **Social Media and Clinical Trial Recruitment**
Eileen O’Brien, Siren Interactive

2:00 p.m. – 2:15 p.m.  **Clinical Trial Enrollment through the New Social Media – Mobil Health Applications**
Joseph Kim, BS, MBA, Shire Pharmaceuticals

2:15 p.m. – 2:30 p.m.  **Digital Tools for Clinical Development – Virtual Clinical Trials and Beyond**
Craig Lipset, MPH, Pfizer Inc.

2:30 p.m. – 2:45 p.m.  **The FDA Perspective**
Russell Katz, MD, U.S. Food and Drug Administration

2:45 p.m. – 3:00 p.m.  **Security and Privacy Pitfalls**
Joanna Napp, Esq., HealthTronics, Inc.

3:00 p.m. – 3:15 p.m.  Break

3:15 p.m. – 3:30 p.m.  **From Ground Zero to PreIND in 3.5 Years: How Social Media Helped Us Get Here**
Lori Sames, Hannah’s Hope Fund, Giant Axonal Neuropathy

3:30 p.m. – 4:30 p.m.  **Panel Discussion: Putting It Together**

4:30 p.m. – 6:30 p.m.  **Information Exchange and Poster Presentation Reception**
Crystal Ballroom – Waterford Suite
Information Exchange and Poster Presentations

Thursday, February 28, 2013
4:30 p.m. - 6:30 p.m. (Opening Reception)
Crystal Ballroom – Waterford Suite
Authors Present

Friday, March 1, 2013
7:30 a.m. - 8:30 a.m.
Crystal Ballroom – Waterford Suite
Posters available for viewing

Since 1999, ASENT has sponsored a poster session of new and previously unpublished data from physicians, researchers and industry leaders in the field of neurotherapeutics. All posters are peer-reviewed and accepted posters will also be published in ASENT’s journal, Neurotherapeutics®. These abstracts are also printed in this program book.

In addition, previously published data, preliminary data and/or previously reviewed posters are also welcome. These posters will not be found in the program book and will not be published in the journal.

The poster session is an opportune time for academicians to showcase potential therapeutic opportunities to the industry and for the industry to provide review data on the progress of their approved or unapproved therapies. Join us in the poster session, and meet the presenters and discuss their projects.

(See the abstract descriptions handout available at the Information Exchange.)

Information Tables

While in the poster session, please take a few minutes to meet with our exhibitors:

American Brain Coalition
American Neurological Association
INC Research
International Essential Tremor Foundation
Parkinson’s Action Network
Springer Science
### THURSDAY, FEBRUARY 28, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 p.m. – 8:30 p.m.</td>
<td><strong>Dinner Session:</strong> Assessment of Benefits and Risks: Deciding Whether to Use a New Medication – Patient and Physician Viewpoints</td>
</tr>
</tbody>
</table>

**Program**

Co-Chairs: Mitchell Brin, MD, Allergan, Inc.; Kathleen Clarence-Smith, MD, PhD, KM Pharmaceutical Consulting LLC

Speakers: James Simsarian, MD, The Neurology Center of Fairfax, Ltd.
Robin Elliott, MA, Parkinson’s Disease Foundation

---

**See You at Next Year’s Meeting**

ASSENT 16th Annual Meeting  
February 20 – 22, 2014  
Bethesda North Marriott Hotel & Conference Center  
Bethesda, Maryland

Abstract submissions begin June 1, 2013
### FRIDAY, MARCH 1, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00 a.m. – 11:45 a.m. | **Barriers in Early Drug Development: Lessons Learned**<br>
**Crystal Ballroom – Haverford Suite**<br>
Program Co-Chairs: Jesse Cedarbaum, MD, Bristol-Meyers Squibb R&D; Amy Chappell, MD, Eli Lilly & Company; Jill Rasmussen, MD, Psi-Napse |
| 8:00 a.m. – 8:30 a.m. | **Of Mice and Men: How Temporal and Other Biological Factors Affect Interpretability of Animal Models**<br>
Gene Kinney, PhD, Prothena Biosciences |
| 8:30 a.m. – 9:00 a.m. | **Using Toxicology and Toxicokinetics to Better Predict Therapeutic Index**<br>
Steve White, PhD, University of Utah |
| 9:00 a.m. – 9:30 a.m. | **Phase 1 Trials: More than Feed and Bleed**<br>
Ajay Verma, MD, PhD, Biogen Idec |
| 9:30 a.m. – 10:00 a.m. | **Phase 2 Trials: What Can Go Wrong When You Think You’ve Get it Right**<br>
Amy Chappell, MD, Eli Lilly & Company |
| 10:00 a.m. – 10:15 a.m. | **Break** |
| 10:15 a.m. – 10:45 a.m. | **A National IRB for Neurodegeneration Studies**<br>
Ara Khachaturian, PhD, Khachaturian, Radebaugh & Associates |
| 10:45 a.m. – 11:15 a.m. | **The Evolving Mission of NINDS Office of Translation**<br>
Rajesh Ranganathan, PhD, NIH/NINDS |
| 11:15 a.m. – 11:45 a.m. | **Panel Discussion** |
### FRIDAY, MARCH 1, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m. – 2:00 p.m.</td>
<td><strong>Special Interest Topics Tables and Luncheon</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Crystal Ballroom – Waterford Suite</strong></td>
</tr>
<tr>
<td></td>
<td>- Health Information Technology (HIT) as a Tool to Enable Comparative Effectiveness Research</td>
</tr>
<tr>
<td></td>
<td>- How Can Phase I Inform Efficacy?</td>
</tr>
<tr>
<td></td>
<td>- What are Appropriate Expectations for Animal Models?</td>
</tr>
<tr>
<td></td>
<td>- How to Most Efficiently Find the Right Dose?</td>
</tr>
<tr>
<td></td>
<td>- How to Use Social Media to Engage Patients in Clinical Research</td>
</tr>
<tr>
<td></td>
<td>- Innovation in Clinical Patient Data Collection: Use of Smart Phones and Other Remote Monitoring Techniques</td>
</tr>
<tr>
<td></td>
<td>- Challenges to Young Researchers Entering the Field of Neurotherapeutics</td>
</tr>
<tr>
<td></td>
<td>- Challenges to International Drug Development</td>
</tr>
<tr>
<td></td>
<td>- How Much Safety Must We Have to Support Marketing Authorization and to Get to Phase III Trials?</td>
</tr>
<tr>
<td></td>
<td>- Challenges for Start-Up Companies to Achieve POC (proof of concept)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2:15 p.m. – 6:00 p.m.</th>
<th><strong>Pipeline Session</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Crystal Ballroom – Haverford Suite</strong></td>
</tr>
</tbody>
</table>

Co-Chairs: Philip Perera, MD, Dart Neuroscience LLC; Michael Rogawski, MD, PhD, University of California, Davis

Investigators in academia, government, industry and advocacy present an update on research and development progress on a specific project in the broad area of neurotherapeutics. Such projects may address neurological disorders, psychiatric disorders, pain, neurooncology, neurological infections or any other disorder affecting the central or peripheral nervous systems.
## Program Schedule (Continued)

**SATURDAY, MARCH 2, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m. – 9:00 a.m.</td>
<td><strong>ASENT Annual Business Meeting</strong></td>
<td><strong>Crystal Ballroom – Haverford Suite</strong></td>
</tr>
<tr>
<td>9:15 a.m. – 11:45 a.m.</td>
<td><strong>New Models for Collaboration: Patients as Drivers and Partners in Neurological Research</strong></td>
<td><strong>Crystal Ballroom – Haverford Suite</strong></td>
</tr>
</tbody>
</table>

### Program

Co-Chairs: C. Anthony Altar, PhD, AssureRx Health, Inc.; Robin Elliott, MA, Parkinson’s Disease Foundation

- **9:15 a.m. – 9:30 a.m.**  
  **Session Introduction and the Patient Perspective**  
  Linda Morgan, MBA, RPh

- **9:30 a.m. – 9:45 a.m.**  
  **How Patient Collaborations Can Drive Innovation**  
  Bray Patrick-Lane, BS, MFS, PFO Foundation

- **9:45 a.m. – 10:00 a.m.**  
  **Partnering with Patients in Study Protocol Development**  
  Kimberly Moran, PhD, UCB, Inc.

- **10:00 a.m. – 10:15 a.m.**  
  **Rethinking Recruitment and Retention Through Patients Engagement**  
  Petra Kaufmann, MD, NIH/NINDS

- **10:15 a.m. – 10:30 a.m.**  
  Break

- **10:30 a.m. – 10:45 a.m.**  
  **Integrating Patient Input Within the Drug Approval Process**  
  Russell Katz, MD, U.S. Food and Drug Administration

- **10:45 a.m. – 11:00 a.m.**  
  **Patients as Drivers in Research Prioritization and Funding**  
  Robert Pacifici, PhD, CHDI

- **11:00 a.m. – 11:45 a.m.**  
  **Panel Discussion**

- **11:45 a.m.**  
  **Annual Meeting Adjourns**
Preliminary Agenda

I. Call to Order

II. Financial Report

III. Neurotherapeutics® Journal Report

IV. Membership Report

V. 16th Annual Meeting, February 20 – 22, 2014

VI. Recognition of Outgoing Board Members

VII. Introduction of Incoming Board Members

VIII. Old Business

IX. New Business

X. Adjournment
To obtain a CME certificate for the ASENT 15th Annual Meeting, please access the online evaluation on our website, www.asent.org. A link to the evaluation is on the homepage. Evaluations must be completed by March 29, 2013 in order to receive credit.

ASENT’s 15th Annual Meeting has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Vermont and the American Society for Experimental NeuroTherapeutics. The University of Vermont is accredited by the ACCME to provide continuing medical education for physicians.

The University of Vermont designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Your number of credits will be determined based on the questions you answer in the online evaluation.
Session Objectives: At the completion of the meeting, participants will be able to:

- Recognize that neurostimulation is being actively developed as a treatment for many neurological disorders and is a treatment option for some;

- Understand how social media is being used by patients to communicate their medical concerns and to gather medical information, and will be aware of how social media can be utilized to facilitate the enrollment and conduct of clinical trials.

Meeting Disclaimer: Regarding written materials and information received, written or otherwise, during this activity: The scientific views, statements and recommendations expressed during this CME activity represent those of the authors, and speakers and do not necessarily represent the views of the University of Vermont.

Interest Disclosures: As an organization accredited by the ACCME to sponsor continuing medical education activities, The University of Vermont is required to disclose any real or apparent conflicts of interest (COI) that any speakers may have related to the content of their presentations.

The University of Vermont requires that each speaker participating in a program designated for AMA Physician’s Recognition Award Category 1 credit disclose any financial interest/arrangement or affiliation with a corporate organization that may impact on his/her presentation (i.e. grants, research support, honoraria, member of speakers’ bureau, consultant, major stock shareholder, etc.)

No Interests to Disclose:

- C. Anthony Alter, PhD**
- Mitchell Brin, MD**
- Amy Chappell, MD**
- C. Anthony Alter, PhD**
- Mitchell Brin, MD**
- Amy Chappell, MD**
- Robert Hamill, MD**
- Leigh Hochberg, MD, PhD
- Russell Katz, MD
- Petra Kaufmann, MD, MSc
- Ara Khachaturian, PhD
- Joseph Kim
- Gene Kinney, PhD
- Victor Krauthamer, PhD
- Bennett Lavenstein, MD**
- Craig Lipset, MPH
- Linda Morgan
- Martha Morrell, MD**
- Eileen O’Brien
- Robert Pacifici, PhD
- Bray Patrick-Lake, MFS
- Philip Perera, MD**
- Rajesh Ranganathan, PhD
- Jill Rasmussen, MD**
- John Reppas, MD, PhD
- Michael Rogawski, MD, PhD**
- Lori Sames
- Nancy Santilli, MSN**
- James Simsonian, MD
- Barbara Slusher, PhD**
- William Theodore, MD**
- Ajay Verma, MD, PhD
- Marc Walton, MD, PhD**
Interests to Disclose/COI/Bias Resolved*:

Jesse Cedarbaum, MD**
    Elan Pharmaceuticals

Kathleen Clarence-Smith, MD, PhD**
    Chase Pharmaceuticals; Kurma Bofnd; Key Neuroscience

Shaun Comfort, MD**
    KAI-Amgen; Incline Therapeutics; Medivation; Cyberonics; RHI

Jacqueline French, MD**
    Grant funding from several sources

Jaimie Henderson, MD
    Nevro Corp.; Proteus Biomedical

Cameron McIntyre, PhD
    IntElect Medical Inc.; Boston Scientific Neuromodulation Corp.

Joanna Napp, JD, MPH
    Endo Pharmaceutical

Roger Porter, MD**
    GSK; Lilly; NeruPace; Upsher-Smith; Valent; Zalicus

H. Steve White, PhD
    SynapCell; Upsher-Smith Laboratories; Janssen Pharmaceuticals;
    NeuroAdjuvants, Inc.; UCB Pharma

*Having a financial interest or other relationship with a corporate organization may not prevent a speaker from making a presentation; however, the existence of the relationship must be made known to the Program Committee prior to the conference so that any possible conflict of interest may be resolved prior to the talk.

**ASENT Program Committee
15th Annual Meeting
Program Committee

Bennett Lavenstein, MD, Co-Chair
Children’s Hospital Medical Center

Martha Morrell, MD, Co-Chair
NeuroPace, Inc.

C. Anthony, Altar, PhD
AssureRx Health Inc.

Mitchell Brin, MD
Allergan, Inc.

Jesse Cedarbaum, MD
Bristol-Myers Squibb

Amy Chappell, MD
Eli Lilly & Company

Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

Shaun Comfort, MD, MBA
Adaptix Clinical Solutions, LLC

Robin Elliott, MA
Parkinson’s Disease Foundation

Robert Hamill, MD
University of Vermont

Philip Perera, MD
Dart Neuroscience LLC

Roger Porter, MD

Jill Rasmussen, MD
Psi-Napse

Michael Rogawski, MD, PhD
University of California, Davis

Barbara Slusher, PhD, MBA
Brain Science Institute, Johns Hopkins School of Medicine

William H. Theodore, MD
National Institutes of Health

Marc Walton, MD, PhD
Food and Drug Administration
American Society for
Experimental NeuroTherapeutics

ASENT 2012 - 2013
Board of Directors

PRESIDENT
Michael Rogawski, MD, PhD
University of California, Davis

PRESIDENT-ELECT
Howard Federoff, MD, PhD
Georgetown University

IMMEDIATE PAST PRESIDENT
Robert W. Hamill, MD
University of Vermont

SECRETARY
Jacqueline French, MD
NYU Comprehensive Epilepsy Center

TREASURER
Robin Elliott, MA
Parkinson’s Disease Foundation

DIRECTORS 2010-2013
Jesse Cedarbaum, MD
Bristol-Myers Squibb
Joseph Hulihan, MD
Ortho-McNeil Janssen Scientific Affairs
Joseph Masdeu, MD, PhD
National Institutes of Health/NIMH-CBDB
Bernard Ravina, MD
Biogen Idec, Inc.

DIRECTORS 2011-2014
Rohit Bakshi, MD, FAAN
Brigham and Women’s Hospital
Russell Katz, MD
FDA Center for Drug Evaluation & Research

Jill Rasmussen, MD
Psi-Napse
Richard Rudick, MD
Cleveland Clinic

DIRECTORS 2012-2015
Steven DeKosky, MD
University of Virginia School of Medicine
Robert Griggs, MD
University of Rochester
Philip Perera, MD, MBA
Dart NeuroScience LLC

EX-OFFICIO
DEVELOPMENT COMMITTEE CHAIR
Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

NEUROTHERAPEUTICS® EDITOR-IN-CHIEF
Alan Faden, MD
University of Maryland School of Medicine

PROGRAM COMMITTEE CO-CHAIRS
Bennett Lavenstein, MD
Children’s Hospital Medical Center
Martha Morrell, MD
NeuroPace, Inc.

NIH BLUEPRINT COURSE LIAISON
Barbara Slusher, PhD, MBA
Johns Hopkins School of Medicine

EXECUTIVE DIRECTOR
M. Suzanne Berry, MBA, CAE

ASSOCIATE DIRECTOR
Anne L. Mercer
Schedule-At-A-Glance

**Thursday, February 28, 2013**

7:30 a.m. – 6:00 p.m.  
Registration  
Crystal Ballroom Foyer  
(Continental Breakfast 7:30 a.m. – 8:30 a.m.)

8:00 a.m. – 12:00 p.m.  
Clinical Neurostimulation for CNS Diseases: From Basic Mechanisms to Current Therapeutics  
Crystal Ballroom — Haverford Suite

12:00 p.m. – 1:30 p.m.  
Lunch – On Your Own

1:30 p.m. – 4:30 p.m.  
Brave New World: Use of the Internet and Social Media to Conduct Clinical Trials  
Crystal Ballroom — Haverford Suite

4:30 p.m. – 6:30 p.m.  
Information Exchange and Poster Presentation Reception

6:30 p.m. – 8:30 p.m.  
Dinner Session: Assessment of Benefits and Risks: Deciding Whether to Use a New Medication – Patient and Physician Viewpoints  
Crystal Ballroom — Haverford Suite

**Friday, March 1, 2013**

7:30 a.m. – 6:00 p.m.  
Registration  
Crystal Ballroom Foyer

7:30 a.m. – 8:30 a.m.  
Continental Breakfast  
Crystal Ballroom — Waterford Suite

8:00 a.m. – 11:45 a.m.  
Barriers in Early Drug Development: Lessons Learned  
Crystal Ballroom — Haverford Suite

12:00 p.m. – 2:00 p.m.  
Special Interest Topics Tables and Luncheon  
Crystal Ballroom — Waterford Suite

2:15 p.m. – 6:00 p.m.  
Pipeline Session  
Crystal Ballroom — Haverford Suite

**Saturday, March 2, 2013**

8:00 a.m. – 12:00 p.m.  
Registration  
(Continental Breakfast 8:15 a.m. – 9:15 a.m.)  
Crystal Ballroom Foyer

8:30 a.m. – 9:00 a.m.  
Annual Business Meeting  
All members are welcome!  
Crystal Ballroom — Haverford Suite

9:15 a.m. – 11:45 a.m.  
New Models for Collaboration: Patients as Drivers and Partners in Neurological Research  
Crystal Ballroom — Haverford Suite

ASENT
342 North Main Street, Suite 301  
West Hartford, CT 06117-2507  
Phone: 860-586-7570  
Fax: 860-586-7550  
Email: info@asent.org  
www.asent.org